Lewis X (Lex, CD15, SSEA-1) is a trisaccharide carbohydrate antigen with the structure Galβ(1-4)[Fucα(1-3)]GlcNAc, prominently expressed on glycoconjugates in neural stem cells, granulocytes, and various tumors. This glycan serves as a marker of undifferentiated cells and mediates key cellular processes through its fucosylated motif. Biosynthesis involves fucosyltransferase 9 (FUT9), which adds the fucose residue to N-glycans, as demonstrated in neural stem cell studies where FUT9 suppression depleted Lex and impaired proliferation.
Functions in Stem Cell Maintenance
In mouse embryonic neural stem cells, Lex on N-glycans activates the Notch signaling pathway, upregulating Musashi-1 to promote proliferation and maintain stemness without inducing apoptosis. Pax6 regulates FUT9 expression, linking Lex to self-renewal and neurogenesis in the developing brain. Lex also supports cellular aggregation and migration in neural stem cells, highlighting its role in early neural development.
Roles in Immunity and Inflammation
Lex on polymorphonuclear granulocytes facilitates adhesion during immune responses, with expression on monocytes and activated lymphocytes aiding extravasation. Unlike its sialylated counterpart (sialyl Lex), Lex acts as a marker rather than a primary selectin ligand in inflammation. High expression occurs in normal epithelia, underscoring its physiological prevalence beyond pathology.
Implications in Cancer and Metastasis
Aberrant Lex expression appears on tumors like colon, breast carcinoma, and leukemia, where it contributes to glycoprotein modifications alongside sialyl Lex on mucins such as MUC1. While sialyl Lex drives metastasis via E-selectin binding, Lex shows dual roles, with antibodies distinguishing it in tumor profiling. Studies position Lex as a target for cancer immunotherapy, often alongside Ley.

